IRDye700Dx (Maleimide) 

IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells^[1].

Incubation of HER2 Affibody with IRDye700Dx Maleimide (5-fold molar excess; 2 h) successfully yields purified HER2 Affibody-IR700Dye conjugates^[1].
HER2 Affibody-IR700Dye conjugate (0.1-0.3 μM; 2 h) induces selective cytotoxicity in HER2-positive SK-BR3, MDA-MB361 and JIMT1 breast cancer cells, but exerts no such effect in HER2-negative MCF7 breast cancer cells when used for near-infrared photoimmunotherapy (NIR-PIT)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

The HER2 Affibody-IR700Dye conjugate (i.v.), formed by coupling IRDye700DX Maleimide with HER2 Affibody, can specifically bind to HER2-positive MDA-MB361 breast cancer tumors in athymic mice (via intravenous injection), generating a significantly higher fluorescent signal than that from HER2-negative MCF7 tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1979.28

C₇₆H₉₉N₁₃Na₄O₂₆S₆Si₃

C[Si](CCC[N+](CCC[S](=O)(O[Na])=O)(CCC[S](=O)(O[Na])=O)CCC[S](=O)([O-])=O)(C)[O-][Si+4]12([N-]3C4=NC(C5=CC=CC=C65)=[N]1C6=NC7=C(C=CC=C8)C8=C9[N-]27)([N](C%10=N9)=C(C%11=CC=CC=C%10%11)N=C3C%12=CC=CC(OCCCOC(NCCCCCC(NCCN%13C(C=CC%13=O)=O)=O)=O)=C4%12)[O-][Si](C)(C)CCC[N+](CCC[S](=O)(O[Na])=O)(CCC[S](=O)(O[Na])=O)CCC[S](=O)([O-])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yamaguchi H, et al. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. Int J Mol Sci. 2021;22(22):12213. Published 2021 Nov 11.  [Content Brief]